The RA 27/3 strain of rubella virus was developed at The Wistar Institute. The seed stock from RA 27/3 has been successfully used worldwide since the 1970's as a vaccine for the prevention of rubella infection. This vaccine has been administered alone and as part of a combination vaccine (e.g. MMR; measles, mumps, rubella vaccine).
The Wistar Institute has maintained seed stocks of the RA/ 27/3 strain of rubella for use in production of vaccines. These vaccines have been licensed to regional public health agencies and to for-profit companies who are developing vaccines for local distribution, particularly in Asia and South America.
The RA 27/3 seed stock may be used for development of vaccines that may be available at a lower cost than those vaccines produced by the major pharmaceutical companies.
The Wistar Institute can provide the proprietary biological material used to make the vaccines.
The RA27/3 strain of rubella virus is available for licensing outside of the United States.